

1 **Thromboembolism risk among patients with diabetes/stress hyperglycemia and COVID-**
2 **19**

3 Stefania L Calvisi^{1§}; Giuseppe A Ramirez^{2,3§}; Marina Scavini⁴; Valentina Da Prat¹; Giuseppe
4 Di Lucca¹; Andrea Laurenzi^{4,5}; Gabriele Gallina^{1,3}; Ludovica Cavallo^{1,3}; Giorgia Borio^{1,3};
5 Federica Farolfi^{1,3}; Maria Pascali^{1,3}; Jacopo Castellani^{1,3}; Vito Lampasona⁴; Armando
6 D'Angelo^{3,6}; Giovanni Landoni^{3,7}; Fabio Ciceri^{3,7}; Patrizia Rovere Querini^{3,5}; Moreno
7 Tresoldi^{1*}; Lorenzo Piemonti^{3,4*}

8
9 ¹ Unit of General Medicine and Advanced Care, IRCCS Ospedale San Raffaele, Milan, Italy

10 ² Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele
11 Scientific Institute, Milan, Italy

12 ³ Università Vita-Salute San Raffaele, Milan, Italy

13 ⁴ Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

14 ⁵ Unit of Internal Medicine and Endocrinology, IRCCS Ospedale San Raffaele, Milan, Italy

15 ⁶ Coagulation service and Thrombosis Research Unit, IRCCS Ospedale San Raffaele, Milan,
16 Italy

17 ⁷ Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute,
18 Milan, Italy

19 ⁸ Hematology and Bone Marrow Transplantation Unit, IRCCS Ospedale San Raffaele, Milan,
20 Italy.

21
22 § SLC and GAR equally contributed to this work ; * MT and LP equally contributed to this
23 work

24
25 **ORCID**

26 0000-0002-9685-4582: SL Calvisi; 0000-0002-2889-366X: GA Ramirez; 0000-0002-7983-
27 6905: M Scavini; 0000-0001-8783-1904: V Da Prat; 0000-0001-5162-8445: V Lampasona;
28 0000-0002-9857-4509: A D'Angelo; 0000-0002-8594-5980: G Landoni; 0000-0003-2615-
29 3649: P Rovere-Querini; 0000-0003-0873-0123: F Ciceri; 0000-0003-1541-6650: M Tresoldi
30

31 **Short title:** Thromboembolism, diabetes and COVID-19

32
33 **Keywords:** COVID-19, diabetes, clinical outcome, humoral response, SARS-CoV-2,
34 Thromboembolism.

35
36 **Correspondence to:** Lorenzo Piemonti, Diabetes Research Institute, San Raffaele Scientific
37 Institute, Via Olgettina 60, 20132 Milan, Italy. Tel: 39 02 26432706, Fax: 39 02 26432871, E-
38 mail: piemonti.lorenzo@hsr.it

39
40 Word count: abstract: 245; text: 3,196;

41 Table: 2

42 Figure: 2

43 **ABSTRACT**

44 **Purpose.** Individuals with diabetes/stress hyperglycemia carry an increased risk for adverse
45 clinical outcome in case of SARS-CoV-2 infection. The purpose of this study was to evaluate
46 whether this risk is, at least in part, modulated by an increase of thromboembolic
47 complications.

48 **Methods.** We prospectively followed 180 hospitalized patients with confirmed COVID-19
49 pneumonia admitted to the Internal Medicine Units of San Raffaele Hospital. Data from 11
50 out of 180 patients were considered incomplete and excluded from the analysis. We analysed
51 inflammation, tissue damage biomarkers, hemostatic parameters, thrombotic events (TEs) and
52 clinical outcome according to the presence of diabetes/stress hyperglycemia.

53 **Results.** Among 169 patients, 51 (30.2%) had diabetes/stress hyperglycemia. Diabetes/stress
54 hyperglycemia and fasting blood glucose (FBG) were associated with increased inflammation
55 and tissue damage circulating markers, higher D-dimer levels, increased prothrombin time
56 and lower antithrombin III activity. Forty-eight venous and 10 arterial TEs were identified in
57 49 (29%) patients. Diabetes/stress hyperglycemia (HR 2.71, $p=0.001$), fasting blood glucose
58 (HR 4.32, $p<0.001$) and glucose variability (HR 1.6, $p < 0.009$) were all associated with an
59 increased risk of thromboembolic complication. TEs significantly increased the risk for an
60 adverse clinical outcome only in the presence of diabetes/stress hyperglycemia (HR 3.05,
61 $p=0.01$) or fasting blood glucose ≥ 7 mmol/l (HR 3.07, $p=0.015$).

62 **Conclusions.** Thromboembolism risk is higher among patients with diabetes/stress
63 hyperglycemia and COVID-19 pneumonia and is associated to poor clinical outcome. In case
64 of SARS-Cov-2 infection patients with diabetes/stress hyperglycemia could be considered for
65 a more intensive prophylactic anticoagulation regimen.

66 **INTRODUCTION**

67 Diabetes has been confirmed as one of the most consistent risk factors for severe disease in
68 case of SARS-CoV-2 infection^{1, 2}. In fact, the risk of admission to an Intensive Care Unit
69 (ICU) and of in-hospital mortality are increased two to three fold by the presence of diabetes
70 in patients with COVID 19 pneumonia³. Different pathophysiological mechanisms were
71 suggested to explain the worse clinical outcome, including hyperglycemia, older age and the
72 presence of comorbidities (i.e., hypertension, obesity, and cardiovascular disease)⁴. However,
73 because of the syndromic nature of diabetes, additional potential causative factors should be
74 considered, such as the increased susceptibility to hyperinflammation⁵, the diminished
75 immunological function⁶ and the prothrombotic state⁷ associated with hyperglycemia. We
76 recently investigated whether diabetes or hyperglycemia are linked to a defect in the humoral
77 immune response against SARS-CoV-2^{8, 9}. Our data showed that the antibody response
78 against multiple SARS-CoV-2 antigens in patients with diabetes is superimposable in terms of
79 timing, persistence, classes, titers, and neutralizing activity to that of non-diabetic patients^{9, 10}.
80 However, in our cohort of patients with SARS-CoV-2 pneumonia, we also observed a
81 significant correlation between serum D-dimer levels and diabetes/hyperglycaemia, a finding
82 confirmed also by others¹¹⁻¹³. Elevated D-dimer levels are a direct consequence of increased
83 fibrin formation and lysis and thus an indicator of increased thrombotic activity, such as
84 disseminated intravascular coagulation (DIC) and thromboembolism¹⁴. COVID-19 is
85 associated with an increased risk of arterial and venous thrombosis¹⁵⁻¹⁷ because of a
86 multitude of factors, including systemic inflammation, endothelial dysfunction, platelet
87 activation, immobilization, mechanical ventilation and the use of central venous catheters¹⁸⁻²⁰.
88 Since diabetes is associated with a pro-thrombotic status⁷ and elevated D-dimer levels¹², we
89 hypothesized that diabetes is associated with an increased risk of thrombotic events (TEs) in
90 patients with COVID-19 pneumonia. To prove this hypothesis we designed a prospective
91 observational study in a cohort of 180 consecutively hospitalized patients with COVID-19

92 pneumonia, focusing on TEs which occurred during hospitalization and risk factors associated
93 with these events.

94

95 **MATERIAL AND METHODS**

96 **Study population and data sources.** The study population consisted of 180 adult patients
97 (≥ 18 years) with confirmed COVID-19 pneumonia admitted to the Internal Medicine Units of
98 San Raffaele Hospital, Milan, Italy from April to May 2020. Patients were included if they
99 were diagnosed with COVID-19 as per the Chinese management guidelines and the World
100 Health Organization interim guidance^{21, 22}. There was no exclusion criterion. A confirmed
101 infection case was defined as a SARS-CoV-2-positive RT-PCR test from a nasal/throat swab,
102 and/or signs, symptoms and radiological findings suggestive of COVID-19 pneumonia.
103 Within 48 hours from admission, we recorded demographic information, clinical features and
104 laboratory exams on the day of admission on a dedicated data collection form. Data were
105 recorded until hospital discharge or death, whichever occurred first. Data were cross-checked
106 in blind and verified by data managers and clinicians for accuracy. We also recorded mortality
107 beyond hospital discharge clinic: for patients non attending our dedicated outpatient follow-
108 up clinic, we checked patient's vital status with either family members or family physician.
109 The study was approved by the local Institutional Review Board (protocol n 34/int/2020;
110 NCT04318366). A standard written informed consent was requested to all patients for their
111 data use.

112 **Thrombotic complications.** The occurrence of any thrombotic event (TE) throughout the
113 hospitalization was the primary outcome of the study. Thrombotic complications included
114 deep vein thrombosis (DVT), pulmonary embolism (PE), and lower and upper limb ischemia,
115 catheter-related thrombosis with deep vein involvement, mesenteric ischemia, stroke and
116 myocardial infarction. A standard protocol to assess patients for thrombotic complications
117 was implemented based on the position paper from the Italian Society on Thrombosis and

118 Haemostasis (SISSET) ²³ and to the interim guidance to recognition and management of
119 coagulopathy in COVID-19 from the International Society on Thrombosis and Hemostasis
120 (ISTH) ²⁴. A close control of hemostasis parameters and clinical signs and symptoms was
121 methodically pursued. Additional investigations, including CT scan and/or ultrasound, were
122 performed on the basis of clinical suspicion of thromboembolic events: (i) elevated D-dimer
123 levels and/or (ii) presence of respiratory failure and/or (iii) presence of symptoms suggestive
124 of TEs. All patients received thromboprophylaxis with enoxaparin 4,000 IU/day [adjusted to
125 6,000 IU/day or 3,000 IU/day in overweight (>100 kg) or underweight (<50kg) subjects,
126 respectively] or, alternatively, with mechanical compression of the lower limbs in case of
127 anticoagulant contraindications (active bleeding and platelet count less than $25 \times 10^9/l$). If
128 chronic oral anticoagulant therapy with direct oral anticoagulants (DOACs) or
129 warfarin/acenocoumarol (OAT) was prescribed prior to admission, it was changed to LMWH
130 anticoagulant treatment. Thromboprophylaxis was administered on admission and during the
131 entire duration of the hospital stay. Anti-Xa measurement was used to monitor anticoagulant
132 treatment. There were no cases of heparin-induced thrombocytopenia. No major
133 haemorrhagic event occurred in patients with thromboprophylaxis. The Padua Prediction
134 Score and the IMPROVE Bleeding Risk Assessment Score were used at hospital admission
135 for stratification of the venous thromboembolism and bleeding risks, respectively. A Padua
136 score ≥ 4 identified patients at high risk for venous thromboembolism, an IMPROVE
137 Bleeding Risk Assessment Score ≥ 7 identified patients at increased risk of bleeding. Overt
138 DIC was defined when the ISTH diagnostic score was ≥ 5 ²⁵.

139 **Definition of diabetes/stress hyperglycemia.** Study participants were defined as having
140 diabetes/stress hyperglycaemia if they had a documented diagnosis before the hospital
141 admission for COVID-19 pneumonia [Comorbid diabetes: fasting plasma glucose (FPG) ≥ 7.0
142 mmol/l or HbA_{1c} $\geq 6.5\%$ (48 mmol/mol), or prescription for diabetes medications] or if
143 patients without a previous diagnosis of diabetes had a mean FPG ≥ 7.0 mmol/l. during the

144 hospitalization for COVID-19 pneumonia (stress hyperglycaemia). We computed mean FPG
145 and glucose variability (standard deviation) from all fasting laboratory glucose values
146 measured during hospitalisation.

147 **Laboratory variables** Routine blood tests encompassed serum biochemistry [including renal
148 and liver function, lactate dehydrogenase (LDH) and electrolytes], complete blood count with
149 differential, markers of myocardial damage [troponin T and pro-brain natriuretic peptide
150 (proBNP)], inflammation markers [C-reactive protein (CRP), ferritin, interleukin-6 (IL-6)]
151 and coagulation profile assessment (D-dimer, PT, and PTT). Specific antibodies to different
152 SARS-CoV-2 antigens were tested in a subset of patients by a luciferase immunoprecipitation
153 system (LIPS) assay, as previously described (11). Fibrinogen, antithrombin activity, vWF,
154 homocysteine, protein C and S. D-dimer levels were measured in a subset of patients through
155 a STA-R® automatic coagulation analyser. Age-specific high D-dimer (aD-dimer) was
156 defined as D-dimer levels above 0.5 µg/dl for patients with less than 50 years of age and
157 above their age divided by 100 in patients older than 50 years²⁶.

158 **Statistical analysis.** Continuous variables were presented as median with inter-quartile range
159 (IQR) in parenthesis. Categorical variables were reported as frequency or percent. Continuous
160 variables were compared using the Wilcoxon rank sum or Kruskal-Wallis test. Categorical
161 variables were compared using the Chi-square or Fischer's exact test, as appropriate.
162 Imputation for missing data was not performed. Associations between baseline variables and
163 diabetes was assessed by logistic regression. The effect estimates were reported as Odd Ratios
164 (ORs). Survival was estimated according to Kaplan–Meier. The time-to-event was calculated
165 from the date of symptom onset to the date of the event, or of last follow-up visit, whichever
166 occurred first. We calculated univariate and multivariate Cox proportional hazards models to
167 study the association between patient characteristics with time to thrombotic complication or
168 time to adverse outcome (as defined by composite endpoint of transfer to ICU or death,
169 whichever occurred first). In Cox proportional hazards models, the onset of a thrombotic

170 complication was considered a time-varying covariate. The effect estimates were reported as
171 Hazard Ratios (HRs) with the corresponding 95% CI, estimated according to the Wald
172 approximation. Multivariate analyses were performed including variables significant at the
173 level of <0.1 in the univariate analysis. Two-tailed P values are reported, with P value <0.05
174 indicating statistical significance. All confidence intervals are two-sided and not adjusted for
175 multiple testing. Statistical analyses were performed with the SPSS 24 (SPSS Inc. /IBM) and
176 the R software version 3.4.0 (R Core Team (2020)).

177

178 **RESULTS**

179 **Study participants.** A total of 180 consecutive patients with confirmed COVID-19 were
180 prospectively enrolled. Data from 11 out of 180 (6.11%) patients were considered incomplete
181 and excluded from the analysis. Among the 169 cases included in our study [median hospital
182 stay 17 (8-31) days], 61 patients (36.1%) were treated with non-invasive ventilation and 23
183 (13.6%) accessed an ICU over the hospitalization period. As of January 25, 2021 the median
184 follow-up time after symptoms onset was 222 (95% CI: 211-232) days. Thirty five patients
185 died during follow-up (20.7%). Fifty patients (29.6%) had an adverse in-hospital outcome,
186 according to the composite endpoint of transfer to ICU or death, whichever occurred first.

187 **Baseline characteristics of study population.** The characteristics of study participants,
188 according to diabetes status or glucose levels, are reported in Supplementary Table 1 and
189 Table 2. Stress hyperglycaemia and comorbid diabetes accounted for 11.2% ($n=19$) and
190 18.9% ($n=32$) of the patients, respectively. Higher BMI [OR 1.112 (95% IC 1.03-1.2);
191 $p=0.007$], older age [OR 1.029 x year (95% IC 1.01-1.05); $p=0.013$], and hypertension [OR
192 4.036 (1.04-3.98); $p=0.037$] were all associated with diabetes/stress hyperglycaemia. As for
193 diabetes treatment, 3.9% of subject with comorbid diabetes were being treated with lifestyle
194 modifications, 11.8% with insulin, 39.2% with non-insulin oral or injectable anti-diabetes
195 medications, 7.8% with insulin and oral diabetes medications, while patients with stress

196 hyperglycaemia (37.3%) were untreated. The median time from symptoms onset to hospital
197 admission was 7 (1-12.5) and 5 (1-8) days for patients without and with diabetes/stress
198 hyperglycaemia, respectively ($p=0.33$). On admission, 18.3% ($n=31$) of the patients were
199 taking ACE-inhibitors (25.5% vs 15.3%, $p=0.132$ diabetes/stress hyperglycaemia vs no
200 diabetes), 14.2% ($n=24$) chronic antiplatelet therapy (21.6% vs 11%, $p=0.092$ diabetes/stress
201 hyperglycaemia vs no diabetes) and 18.3% ($n=31$) anticoagulant treatments (23.5% vs 16.1%,
202 $p=0.28$ diabetes/stress hyperglycaemia vs no diabetes).

203 **Hospital admission.** On admission signs of respiratory insufficiency were evident in most
204 patients [PaO₂/FiO₂ ratio 280 (200-368)] and a PaO₂/FiO₂ ratio <200 was present in 20%
205 and 29.4% of patients with or without diabetes/stress hyperglycaemia, respectively ($p=0.31$).
206 Diabetes/stress hyperglycaemia was associated with worse kidney function [serum creatinine:
207 96.4 (65.4-152) vs 82.2 (65.4-106) $\mu\text{mol/L}$, $p=0.039$; urea nitrogen 18.6 (10.5-33.8) vs 11.9
208 (8.66-19.6) mmol/L, $p=0.004$], increased inflammation [CRP 87.5 (35.7-184) vs 53.5 (17.9-
209 112) mg/L; $p=0.009$] and tissue damage markers [LDH 6.65 (4.33-8.8) vs 5.04 (3.82-8.8)
210 $\mu\text{kat/L}$, $p=0.006$; AST 0.82 (0.64-1.35) vs 0.6 (0.43-0.91) $\mu\text{kat/L}$, $p=0.006$; ALT 0.73 (0.45-
211 0.97) vs 0.57 (0.33-0.83) $\mu\text{kat/L}$, $p=0.077$; pro-BNP 738 (193-2238) vs 193 (59-910) ng/L,
212 $p=0.011$; troponin T 19.5 (11.4-61.55) vs 12.7 (6-42.6) $\mu\text{g/L}$, $p=0.078$]. The same changes
213 were associated with progressively higher blood glucose levels (Supplementary Table 2).
214 Data regarding the IgG, IgM and IgA responses to the SARS-CoV-2 spike protein (RBD or
215 S1+S2) and IgG to NP (Table 1) were available for a subgroup of patients, as they were part
216 of a previous cohort evaluated for the humoral response in the presence of diabetes (12).
217 Marginal differences between patients with and without diabetes/stress hyperglycaemia were
218 evident. Over the hospitalization period antibiotic (80.4% vs 61.9%, $p=0.02$) and oxygen
219 (84.3% vs 61%, $p=0.004$) treatments were more frequently used in patients with

220 diabetes/stress hyperglycaemia while antiviral, immunomodulatory and biologic therapies
221 were equally prescribed.

222 **Hemostatic parameters.** Upon admission patients with diabetes/stress hyperglycaemia
223 exhibited significantly higher D-dimer levels [11.8 (5.5-12.4) vs 4.2 (2.3-9.3) $\mu\text{g/ml}$, $p<0.001$]
224 and increased prothrombin time (PT-INR 1.16 (1.02-1.25 vs 1.04 (0.98-1.15), $p=0.001$)
225 compared with patients without diabetes/stress hyperglycaemia (Table 1). Concordantly, the
226 percentage of subject with elevated age-specific D-dimer was significantly higher in the
227 presence of diabetes/stress hyperglycaemia (76.5% vs 56.8%, $p=0.016$). Partial
228 thromboplastin time, platelet count and fibrinogen were not affected by diabetes/stress
229 hyperglycaemia. Advanced markers of thrombophilia were available for a subgroup of
230 patients (Table 1). Exploratory analysis did not show significant changes in coagulation
231 factors levels or activity in subjects with diabetes, except for a lower antithrombin III activity
232 [91% (80-120) vs 100% (92-106)]. The presence of diabetes/stress hyperglycaemia did not
233 significantly increase the proportion of patients who at baseline had a higher risk for venous
234 thromboembolism based on the Padua score (Padua score ≥ 4 : 43.1% vs 31.4%, $p=0.16$), even
235 if a marginal, although significant, difference in the Padua score was evident [3 (3-5) vs 3 (1-
236 5), $p=0.006$] (Table 1). Similarly, the proportion of patients at high baseline bleeding risk
237 based on the IMPROVE score was not affected by the presence of diabetes/stress
238 hyperglycaemia (IMPROVE ≥ 7 : 9.8% vs 5.9%; $p= 0.35$), even if a marginal, although
239 significant, difference in the IMPROVE score was evident [2.2 (1.2-4.1) vs 1.6 (0.97-2.9),
240 $p=0.024$] (Table 1).

241 **Thromboembolic complications.** Forty eight venous and 10 arterial TE were identified in 49
242 (29%) patients (Table 2). The median time from the onset of symptoms of COVID-19
243 pneumonia to the TE was 17 (10-24) days. Patients with diabetes/stress hyperglycaemia
244 developed more frequently a thromboembolic complication (47.1% vs 21.2%, $p=0.001$) than
245 patients without diabetes/stress hyperglycaemia. Comorbid diabetes and stress

246 hyperglycaemia were both associated with a higher prevalence of thromboembolic
247 complication (52% vs 42.1% respectively, $p=0.77$). Concordantly, the higher prevalence of
248 thromboembolic complication was associated with higher fasting blood glucose levels during
249 the hospitalization (Table 1). Regarding the thrombosis site, venous events (in particular deep
250 vein thrombosis) contributed more significantly than arterial ones in determining the higher
251 prevalence of thromboembolic complications in patients with diabetes/stress hyperglycaemia
252 compared to those without diabetes/stress hyperglycaemia. In patients with and without
253 diabetes/stress hyperglycaemia, 3 and 1 (5.9% vs 0.8%, $p=0.083$) events were classified as
254 overt DIC (≥ 5 points, according to the ISTH diagnostic criteria), respectively. The results of a
255 Cox regression analysis for TE is presented in Fig. 1. The Cox regression analysis adjusted
256 for age and sex indicates that diabetes/stress hyperglycaemia (HR 2.71, CI 1.53-4.8; $p=0.001$),
257 fasting plasma glucose [FPG mean (log₁₀) HR 4.32, CI 1.86-10, $p=0.001$] and glucose
258 variability [FPG standard deviation (log₁₀) HR 1.6, CI 1.13-2.28, $p=0.009$] were associated
259 with a higher risk of thromboembolic complications. Differences in smoke habit, BMI, other
260 comorbidities and preadmission antiplatelet or steroid were all statistically not significant. A
261 trend towards a protective effect of preadmission anticoagulant therapy was evident (HR 0.45,
262 CI 0.18-1.08; $p=0.075$). In a multivariate model, diabetes/stress hyperglycaemia and
263 preadmission anticoagulant therapy confirmed their association with the thromboembolic
264 complication.

265 **TEs and adverse clinical outcome in patients with and without diabetes/stress**
266 **hyperglycaemia.** To assess whether the presence of TEs had an impact on patient outcome
267 according to diabetes/stress hyperglycaemia or fasting glucose levels, we conducted a Kaplan-
268 Meier estimator log-rank test and a Cox proportional hazards model for adverse clinical
269 outcome (as defined by composite endpoint of transfer to ICU or death, whichever occurred
270 first) (Figure 2). The Cox regression analysis adjusted for age and *sex* indicated that
271 diabetes/stress hyperglycaemia (HR 2.99, CI 1.7-5.03; $p<0.001$), fasting plasma glucose [FPG

272 mean (log₁p) HR 9.6, CI 4.59-20; p<0.001] and glucose variability [FPG standard deviation
273 (log₁p) HR 2.02, CI 1.43-2.9; p<0.001] were strongly associated with a higher risk of adverse
274 clinical outcome (see also Supplementary Table 2). TEs were not associated with an adverse
275 clinical outcome in the absence of diabetes/stress hyperglycaemia (HR 0.29, CI 0.04-2.16;
276 p=0.225) or in the presence of FBG <7 mmol/l (HR 0.54, CI 0.07-4.35; p=0.56), while they
277 significantly increased the risk in the presence of diabetes/stress hyperglycaemia (HR 3.05, CI
278 1.31-7.09; p=0.01) or FBG ≥ 7 mmol/l (HR 3.07, CI 1.24-7.6; p=0.015).

279

280 **DISCUSSION**

281 There are few reports on the relationship between hyperglycemia and the rate of TEs in
282 COVID-19 pneumonia and it is still unknown whether thrombosis affects the prognosis of
283 patients with COVID-19 pneumonia in the presence of diabetes. Under the hypothesis of a
284 relevant role for diabetes, we designed a prospective observational study focusing on TEs
285 occurring during hospitalization and risk factors associated with thromboembolic
286 complications in patients with COVID-19 pneumonia. Our study generated several interesting
287 findings in those patients. First, diabetes/stress hyperglycaemia, high fasting glycaemia and
288 glycemic variability were strong risk factors for the development of thromboembolic
289 complications. Second, the rate of venous thrombosis events (in particular deep vein
290 thrombosis) was the most affected by the presence of diabetes/stress hyperglycaemia. Third,
291 thromboembolic complications had an adverse impact on clinical outcome exclusively in the
292 presence of diabetes/stress hyperglycaemia. While reasonable, these results could not have
293 been taken for granted²⁷. TEs have a higher incidence among patients with COVID-19²⁸⁻³⁰
294 and diabetes is *per se* characterized by a pro-thrombotic status⁷. We and others have
295 previously reported an increase of D-dimer in patients with diabetes/stress hyperglycaemia
296 and COVID-19 pneumonia compared to those without¹¹⁻¹³. However the clinical implications
297 in term of thromboembolic risk of those findings were yet unclear. Moreover, data on the

298 correlation of thromboembolic complications with clinical outcome were limited and
299 contradictory, with some studies finding a higher risk of adverse outcome associated with TEs
300 in hospitalized patients with COVID-19 ³¹, while others did not find any association ³². The
301 pathophysiological mechanisms related to the increased risk of TEs in patients with
302 COVID-19 pneumonia and diabetes are still incompletely understood. In our study,
303 diabetes/stress hyperglycaemia was associated with both inflammation and coagulopathy
304 (elevated C reactive protein and D-dimer levels, mild prolongation of the prothrombin time
305 and decreased antithrombin III), suggesting that an hyperglycaemia-related amplification of
306 the pathobiological mechanisms of immunothrombosis ³³ could be responsible of the
307 increased thrombotic risk. The reduced activity of antithrombin III is of particular interest in
308 this context ³⁴. In fact, antithrombin III is a powerful natural anticoagulant which is regulated
309 by inflammation ³⁵. Therefore, it can be speculated that hyperinflammation might have been
310 triggering a decrease in antithrombin III levels and its physiological anticoagulant activity.
311 Furthermore, since the clinical anticoagulant efficacy of heparin requires interaction with
312 antithrombin III, an impaired levels/activity of antithrombin III may be associated with
313 “heparin resistance” ³⁵. In agreement with this hypothesis, an association between
314 antithrombin III levels and mortality in patients with COVID-19 pneumonia has already been
315 reported³⁶. An association between thromboembolic complications and the presence of
316 antiphospholipid antibodies in patients with COVID-19 pneumonia has been previously
317 reported in case reports, case series, cohort studies, and cross-sectional studies, although with
318 contradictory results ³⁷. Unfortunately antiphospholipid antibody measurements were
319 available only for a subgroup of our patients and, therefore, it was impossible to include them
320 in a multivariate model to test for their contribution to thromboembolic risk.

321 Our study encompasses some limitations: first, our cohort was limited to hospitalized patients
322 and results could be different in less severe COVID-19 disease. Second, even if the overall
323 venous and arterial thromboembolism rate was similar to that described until now in various

324 studies (18), our monocentric cohort was relatively small, and, therefore, a selection bias
325 cannot be excluded. Third, we were unable to evaluate the specific role of some markers as
326 predictors of thrombosis in multivariate models since a complete set of biochemical
327 coagulation data was available only for a fraction of patients. Nevertheless our study
328 generated additional valuable knowledge about the role of diabetes/stress hyperglycaemia in
329 predicting TEs and in stratifying their prognostic significance. In conclusion, many evidences
330 indicate that patients with diabetes, in case of COVID-19 pneumonia, carry a significant
331 increased risk for adverse clinical outcome when compared with patients without diabetes. It
332 is clear from our study that part of this risk is due to an increase in thromboembolic
333 complications. These findings suggest that in in case of SARS-Cov-2 pneumonia, patients
334 with diabetes/stress hyperglycaemia could be considered for a more intensive prophylactic
335 anticoagulation regimen.

336 *Declaration of interests.* The authors have no conflict of interest to disclose in relation to the
337 topic of this manuscript. The authors declare that there are no relationships or activities that
338 might bias, or be perceived to bias, their work.

339

340 *This work was funded by Program Project COVID-19 OSR-UniSR and Ministero della Salute*
341 *(COVID-2020-12371617).*

342

343 *Individual contributions* LP, SLC and GAR contributed to the conception of the study, wrote
344 the manuscript, researched data and contributed to the discussion. MSc and VL contributed to
345 the acquisition and analysis of antibody data and revised the manuscript. VDP, GDL, AL,
346 PRQ and FC recruited patients, contributed to the acquisition of samples, managed the
347 biobanking activities and critically revised the manuscript, AD and GL contributed to the
348 acquisition, analysis and interpretation of data and critically revised the manuscript. MT
349 contributed to the design of the study and critically reviewed/edited the manuscript. LP is the
350 guarantor of this work and, as such, had full access to all the data presented in the study and
351 takes responsibility for the integrity of the data and the accuracy of the data analysis. The
352 final manuscript has been read and approved by all named authors.

353 **REFERENCES**

- 354 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng
355 Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L,
356 Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J & Cao B. Clinical features of patients
357 infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020 **395** 497-506.
- 358 2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC,
359 Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li
360 SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY,
361 Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY & Zhong NS. Clinical
362 Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020 **382** 1708-
363 1720.
- 364 3. Mantovani A, Byrne CD, Zheng MH & Targher G. Diabetes as a risk factor for greater
365 COVID-19 severity and in-hospital death: A meta-analysis of observational studies.
366 *Nutr Metab Cardiovasc Dis* 2020.
- 367 4. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A & Del Prato S.
368 COVID-19 in people with diabetes: understanding the reasons for worse outcomes.
369 *Lancet Diabetes Endocrinol* 2020.
- 370 5. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K,
371 Zhao L, Fan H, Luo S & Hu D. Diabetes is a risk factor for the progression and
372 prognosis of COVID-19. *Diabetes Metab Res Rev* 2020 e3319.
- 373 6. Geerlings SE & Hoepelman AI. Immune dysfunction in patients with diabetes mellitus
374 (DM). *FEMS Immunol Med Microbiol* 1999 **26** 259-265.
- 375 7. Vazzana N, Ranalli P, Cuccurullo C & Davi G. Diabetes mellitus and thrombosis.
376 *Thromb Res* 2012 **129** 371-377.
- 377 8. Secchi M, Bazzigaluppi E, Brigatti C, Marzinotto I, Tresoldi C, Rovere-Querini P,
378 Poli A, Castagna A, Scarlatti G, Zangrillo A, Ciceri F, Piemonti L & Lampasona V.

- 379 COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2
380 spike receptor binding domain. *J Clin Invest* 2020.
- 381 9. Lampasona V, Secchi M, Scavini M, Bazzigaluppi E, Brigatti C, Marzinotto I, Davalli
382 A, Caretto A, Laurenzi A, Martinenghi S, Molinari C, Vitali G, Di Filippo L, Mercalli
383 A, Melzi R, Tresoldi C, Rovere-Querini P, Landoni G, Ciceri F, Bosi E & Piemonti L.
384 Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an
385 observational cohort study. *Diabetologia* 2020 **63** 2548-2558.
- 386 10. Dispinseri S, Lampasona V, Secchi M, Cara A, Bazzigaluppi E, Negri D, Brigatti C,
387 Pirillo MF, Marzinotto I, Borghi M, Rovere-Querini P, Tresoldi C, Ciceri F, Scavini
388 M, Scarlatti G & Piemonti L. Robust neutralizing antibodies to SARS-CoV-2 develop
389 and persist in subjects with diabetes and COVID-19 pneumonia. *J Clin Endocrinol*
390 *Metab* 2021.
- 391 11. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, Yu X & Dong K. Clinical
392 characteristics and outcomes of patients with severe covid-19 with diabetes. *BMJ*
393 *Open Diabetes Res Care* 2020 **8**.
- 394 12. Mishra Y, Pathak BK, Mohakuda SS, Tilak T, Sen S, P H, Singh R & Singh AR.
395 Relation of D-dimer levels of COVID-19 patients with diabetes mellitus. *Diabetes*
396 *Metab Syndr* 2020 **14** 1927-1930.
- 397 13. Sardu C, D'Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, Maggi P,
398 Coppola N, Paolisso G & Marfella R. Outcomes in Patients With Hyperglycemia
399 Affected by COVID-19: Can We Do More on Glycemic Control? *Diabetes Care* 2020
400 **43** 1408-1415.
- 401 14. Soomro AY, Guerchicoff A, Nichols DJ, Suleman J & Dangas GD. The current role
402 and future prospects of D-dimer biomarker. *Eur Heart J Cardiovasc Pharmacother*
403 2016 **2** 175-184.

- 404 15. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R & Clary B.
405 Thromboembolism risk of COVID-19 is high and associated with a higher risk of
406 mortality: A systematic review and meta-analysis. *EClinicalMedicine* 2020 **29**
407 100639.
- 408 • 16. Wang C, Zhang H, Zhou M, Cheng Y, Ye L, Chen J, Wang M & Feng Z.
409 Prognosis of COVID-19 in patients with vein thrombosis: a systematic review and
410 meta-analysis. *Eur Rev Med Pharmacol Sci* 2020 **24** 10279-10285.
- 411 17. Tang N, Li D, Wang X & Sun Z. Abnormal coagulation parameters are associated
412 with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*
413 2020 **18** 844-847.
- 414 18. Connors JM & Levy JH. Thromboinflammation and the hypercoagulability of
415 COVID-19. *J Thromb Haemost* 2020.
- 416 19. Bozzani A, Arici V, Tavazzi G, Franciscone MM, Danesino V, Rota M, Rossini R,
417 Sterpetti AV, Ticozzelli G, Rumi E, Mojoli F, Bruno R & Ragni F. Acute arterial and
418 deep venous thromboembolism in COVID-19 patients: Risk factors and personalized
419 therapy. *Surgery* 2020 **168** 987-992.
- 420 20. Gu SX, Tyagi T, Jain K, Gu VW, Lee SH, Hwa JM, Kwan JM, Krause DS, Lee AI,
421 Halene S, Martin KA, Chun HJ & Hwa J. Thrombocytopenia and endotheliopathy:
422 crucial contributors to COVID-19 thromboinflammation. *Nat Rev Cardiol* 2020.
- 423 21. China NHC. The diagnosis and treatment plan for the novel coronavirus disease. The
424 seventh edition 2020. 2020.
- 425 22. World_Health_Organization. Clinical management of severe acute respiratory
426 infection when novel coronavirus (nCoV) infection is suspected: interim guidance.
427 2020 **January 2020**.

- 428 23. Marietta M, Ageno W, Artoni A, De Candia E, Gresele P, Marchetti M, Marcucci R &
429 Tripodi A. COVID-19 and haemostasis: a position paper from Italian Society on
430 Thrombosis and Haemostasis (SISST). *Blood Transfus* 2020 **18** 167-169.
- 431 24. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C & Iba T. ISTH
432 interim guidance on recognition and management of coagulopathy in COVID-19. *J*
433 *Thromb Haemost* 2020 **18** 1023-1026.
- 434 25. Taylor FB, Jr., Toh CH, Hoots WK, Wada H & Levi M. Towards definition, clinical
435 and laboratory criteria, and a scoring system for disseminated intravascular
436 coagulation. *Thromb Haemost* 2001 **86** 1327-1330.
- 437 26. Righini M, Van Es J, Den Exter PL, Roy PM, Verschuren F, Ghuyssen A, Rutschmann
438 OT, Sanchez O, Jaffrelot M, Trinh-Duc A, Le Gall C, Moustafa F, Principe A, Van
439 Houten AA, Ten Wolde M, Douma RA, Hazelaar G, Erkens PM, Van Kralingen KW,
440 Grootenboers MJ, Durian MF, Cheung YW, Meyer G, Bounameaux H, Huisman MV,
441 Kamphuisen PW & Le Gal G. Age-adjusted D-dimer cutoff levels to rule out
442 pulmonary embolism: the ADJUST-PE study. *Jama* 2014 **311** 1117-1124.
- 443 27. Wijaya I, Andhika R & Huang I. Hypercoagulable state in COVID-19 with diabetes
444 mellitus and obesity: Is therapeutic-dose or higher-dose anticoagulant
445 thromboprophylaxis necessary? *Diabetes Metab Syndr* 2020 **14** 1241-1242.
- 446 28. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, Kucher N,
447 Studt JD, Sacco C, Bertuzzi A, Sandri MT & Barco S. Venous and arterial
448 thromboembolic complications in COVID-19 patients admitted to an academic
449 hospital in Milan, Italy. *Thromb Res* 2020 **191** 9-14.
- 450 29. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, Merdji
451 H, Clere-Jehl R, Schenck M, Fagot Gandet F, Fafi-Kremer S, Castelain V, Schneider
452 F, Grunebaum L, Angles-Cano E, Sattler L, Mertes PM & Meziani F. High risk of

- 453 thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective
454 cohort study. *Intensive Care Med* 2020 **46** 1089-1098.
- 455 30. Ali MAM & Spinler SA. COVID-19 and thrombosis: From bench to bedside. *Trends*
456 *Cardiovasc Med* 2020.
- 457 31. Zhang L, Feng X, Zhang D, Jiang C, Mei H, Wang J, Zhang C, Li H, Xia X, Kong S,
458 Liao J, Jia H, Pang X, Song Y, Tian Y, Wang B, Wu C, Yuan H, Zhang Y, Li Y, Sun
459 W, Zhu S, Wang S, Xie Y, Ge S, Hu Y & Xie M. Deep Vein Thrombosis in
460 Hospitalized Patients With COVID-19 in Wuhan, China: Prevalence, Risk Factors,
461 and Outcome. *Circulation* 2020 **142** 114-128.
- 462 32. Hippensteel JA, Burnham EL & Jolley SE. Prevalence of venous thromboembolism in
463 critically ill patients with COVID-19. *Br J Haematol* 2020 **190** e134-e137.
- 464 33. Loo J, Spittle DA & Newnham M. COVID-19, immunothrombosis and venous
465 thromboembolism: biological mechanisms. *Thorax* 2021.
- 466 34. Mir N, D'Amico A, Dasher J, Tolwani A & Valentine V. Understanding the
467 andromeda strain - The role of cytokine release, coagulopathy and antithrombin III in
468 SARS-CoV2 critical illness. *Blood Rev* 2020 100731.
- 469 35. Levy JH, Sniecinski RM, Welsby IJ & Levi M. Antithrombin: anti-inflammatory
470 properties and clinical applications. *Thromb Haemost* 2016 **115** 712-728.
- 471 36. Gazzaruso C, Paolozzi E, Valenti C, Brocchetta M, Naldani D, Grignani C, Salvucci
472 F, Marino F, Coppola A & Gallotti P. Association between antithrombin and mortality
473 in patients with COVID-19. A possible link with obesity. *Nutr Metab Cardiovasc Dis*
474 2020 **30** 1914-1919.
- 475 37. El Hasbani G, Taher AT, Jawad A & Uthman I. COVID-19, Antiphospholipid
476 Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association?
477 *Clin Med Insights Arthritis Musculoskelet Disord* 2020 **13** 1179544120978667.
- 478

479 **FIGURE LEGEND**

480 **Figure 1. TEs in patients with COVID-19.** The forest plots (panel a) show the Hazard
481 Ratios (HR) for thrombosis for each factor tested. Upper panel: univariate Cox regression
482 analysis adjusted for sex and age. Lower panel: multivariate Cox regression analysis adjusted
483 for sex and age including variables significant at the level of <0.1 in the univariate analysis.
484 Dots represent the HR, lines represent 95% confidence interval (CI), and solid dots indicate P
485 < 0.05 . Kaplan-Meier thrombosis-free survival estimates for patients with COVID-19
486 pneumonia (panel b). Survival rate was estimated for the presence of diabetes. The log-rank
487 test was used to test differences in the estimated survival rate. Crosses indicate censored
488 patients (censoring for death end of follow-up data).

489

490 **Figure 2. Survival in the absence of adverse clinical outcome in patients with COVID-19**
491 **with or without TEs, according to diabetes/stress hyperglycemia or fasting glucose**
492 **levels.** Kaplan-Meier patient survival estimates for 169 patients with COVID-19 pneumonia
493 (panel a). Survival rate in the absence of adverse clinical outcome (defined by composite
494 endpoint of transfer to ICU or death, whichever occurred first) was estimated for the presence
495 of any thrombotic event (TE) separately according diabetes/stress hyperglycemia or fasting
496 glucose levels. The log-rank test was used to test differences in the estimated survival rate
497 between groups. Crosses indicate censored patients (censoring for death or end of follow-up
498 data). The forest plots (panel b) show the hazard ratios for survival in the absence of adverse
499 clinical outcome according to presence/absence of diabetes/stress hyperglycemia or fasting
500 glucose levels (FBG) categories. The presence of thrombotic events (TE) was considered as a
501 time-varying covariate in Cox proportional hazards models. The effect estimates were
502 reported as Hazard Ratios (HRs) with the corresponding 95% CI, estimated according to the
503 Wald approximation. Cox regression analysis was adjusted for sex and age. Dots represent
504 the HR, lines represent 95% confidence interval (CI), and solid dots indicate $P < 0.05$.

Table 1. Hemostatic parameters, inflammation markers and SARS-Cov2 antibodies according to diabetes/stress hyperglycemia and median fasting plasma glucose

Characteristics	All	Diabetes/stress hyperglycemia		p	Median fasting glucose (mmol/l)			p	Missing
		No	Yes		<5.6	5.6-6.9	≥ 7		
N		118	51		90	37	42		
Platelets (x10 ⁹ /L)	225 (153-307)	230 (157-309)	212 (151-301)	0.61	229 (157-379)	200 (160-321)	225 (146-324)	0.90	1
D-dimer (µg/ml)	5.9 (2.8-16.6)	4.2 (2.3-9.3)	11.8 (5.5-12.4)	<0.001	4.16 (2.3-9)	5.75 (2.35-11.4)	15.1 (6-35.6)	<0.001	0
Elevated aD-dimer [N (%)]	106 (62.7)	67 (56.8)	39 (76.5)	0.016	51 (56.7)	21 (56.8)	34 (81)	0.019	0
C reactive protein (mg/l)	57.5 (20.7-128.6)	53.5 (17.9-112)	87.5 (35.7-184)	0.009	35.4 (11.7-92.5)	69.1 (54-130)	117 (47.2-204)	<0.001	4
PT-INR	1.06 (0.99-1.2)	1.04 (0.98-1.15)	1.16 (1.02-1.25)	0.001	1.04 (0.98-1.17)	1.06 (0.97-1.16)	1.17 (1.04-1.27)	0.005	4
PTT-R	0.99 (0.94-1.05)	1 (0.95—1.05)	0.98 (0.91-1.06)	0.52	0.99 (0.94-1.05)	1.01 (0.95-1.1)	0.97 (0.9-1.06)	0.27	4
Ferritin µg/L	903 (387-1514)	804 (331-1450)	1058 (484-1689)	0.17	700 (308-1115)	1367 (447-2492)	1092 (588-1821)	0.003	29
IL-6 (pg/ml)	43.3 (15.4-98.5)	43.7 (13.2-95.85)	41.5 (22-124)	0.26	39.2 (9.5-86)	74.3 (13.4-131)	41.4 (26.7-153)	0.12	44
Fibrinogen (g/L)	5.53 (4.19-6.39)	5.46 (4.16-6.19)	5.65 (4.18-7.34)	0.24	5.11 (3.89-5.85)	5.87 (5.57-6.59)	5.75 (4.78-7.46)	0.004	42
von Willebrand factor (%)	307 (190-379)	306 (212-377)	336 (165-420)	0.92	307 (191-376)	301 (176-372)	358 (184-420)	0.49	101
Protein C (%)	86 (72-106)	86 (77-103)	73.5 (53-111)	0.24	87 (76-104)	82.5 (72-93)	78.5 (53-111)	0.59	96
Protein S (%)	78 (60-98)	82 (60-98)	68 (56-94)	0.36	84 (61.5-101.5)	78.5 (59-94.5)	68 (63-88.5)	0.56	98
Antithrombin III (%)	98 (88-106)	100 (92-106)	91 (80-102)	0.041	100 (88.25-105)	98 (93-109)	89 (79-104)	0.23	95
Homocysteine (µmol/L)	14.8 (10.1-19.4)	14.4 (10-18.4)	16.5 (12.3-23.5)	0.17	13.4 (10-16)	19.4 (10-24)	15.4 (9.9-21.7)	0.140	102
Padua score	3 (2-5)	3(1-5)	3 (3-5)	0.006	3 (1-5)	3 (1.5-4.5)	3 (3-5)	0.049	0
Padua score ≥ 4 [N (%)]	59 (34.9)	37 (31.4)	22 (43.1)	0.16	30 (33.3)	11 (29.7)	18 (42.9)	0.43	0
IMPROVE score	2 (1-3)	1.6 (0.97-2.9)	2.2 (1.2-4.1)	0.024	1.6 (0.9-2.9)	1.5 (11-2.9)	2.2 (1.42-4.02)	0.15	0
IMPROVE score ≥ 7 [N (%)]	12 (7.1)	7 (5.9)	5 (9.8)	0.35	7 (7.8)	1 (2.7)	4 (9.5)	0.47	0
DIC by ISTH definitions [N (%)]	4 (2.4)	1 (0.8)	3 (5.9)	0.083	0 (0)	1 (2.7)	3 (7.1)	0.042	0
IgG RBD [N (%)]	45 (51.1)	30 (47.6)	15 (60)	0.349	24 (50)	8 (47.1)	13 (56.5)	0.817	81
IgM RBD [N (%)]	46 (52.3)	33 (52.4)	13 (52)	0.99	24 (50)	10 (58.8)	12 (52.2)	0.822	81
IgA RBD [N (%)]	44 (50)	27 (42.9)	17 (68)	0.057	19 (39.6)	9 (52.9)	16 (69.6)	0.059	81
IgG S1/S2	53 (60.2)	36 (57.1)	17 (68)	0.470	28 (58.3)	10 (58.8)	15 (65.2)	0.850	81
IgM S1/S2	61 (69.3)	42 (66.7)	19 (76)	0.452	33 (68.8)	11 (64.7)	17 (73.9)	0.816	81
IgA S1/S2	66 (75)	45 (71.4)	21 (84)	0.281	34 (70.8)	13 (76.5)	19 (82.6)	0.556	81
IgG NP	58 (65.9)	42 (66.7)	16 (64)	0.808	31 (64.6)	12 (70.6)	15 (65.2)	0.901	81

DIC disseminated intravascular coagulation; INR: international normalized ratio ISTH: International Society of Thrombosis and Haemostasis; PT prothrombin time; PTT: partial thromboplastin time.

Table 2: Thrombotic events (TEs)

	Diabetes/stress hyperglycemia					Median fasting glucose (mmol/l)					
	All	No	Yes	p	Comorbid diabetes	Stress hyperglycemia	p	<5.6	5.6-6.9	≥ 7	p
N	169	118	51		32	19		90	37	42	
Patients with at least one event [N (%)]	49 (29)	25 (21.2)	24 (47.1)	0.001	16 (50)	8 (42.1)	0.77	20 (22.2)	9 (24.3)	20 (47.6)	0.009
Median time from symptoms to thrombosis	17 (10-24)	11 (2-20)	18 (8-28)	0.11	21 (11-31)	11 (0-28)	0.44	13 (4-22)	6 (0-12)	18 (3-33)	0.19
Arterial events [N (%)]											
- Myocardial infarction	3 (1.8)	1 (0.8)	2 (3.9)	0.22	2 (6.3)	0 (0)	0.52	0 (0)	2 (5.4)	1 (2.4)	0.10
- Stroke	1 (0.6)	0 (0)	1 (2)	0.30	1 (3.1)	0 (0)	0.99	0 (0)	0 (0)	1 (2.4)	0.19
- Limb ischaemia	6 (3.6)	4 (3.4)	2 (3.9)	0.99	1 (3.1)	1 (5.3)	0.99	4 (4.4)	0 (0)	2 (4.8)	0.42
- Intestinal ischaemia	0 (0)	0 (0)	0 (0)	-	0 (0)	0 (0)	-	0 (0)	0 (0)	0 (0)	-
Total patients with arterial event	10 (5.9)	5 (4.2)	5 (9.8)	0.17	4 (12.5)	1 (5.3)	0.64	4 (4.4)	2 (5.4)	4 (9.5)	0.51
Venous events [N (%)]											
- Isolated spontaneous DVT	17 (10.1)	6 (5.1)	11 (21.6)	0.004	8 (25)	3 (15.8)	0.50	6 (6.7)	3 (8.1)	8 (19)	0.08
- Isolated PVT	15 (8.9)	8 (6.8)	7 (13.7)	0.15	4 (12.5)	3 (15.8)	0.99	4 (4.4)	5 (13.5)	6 (14.3)	0.096
- DVT+ PVT	8 (4.7)	6 (5.1)	2 (3.9)	0.99	1 (3.1)	1 (5.3)	0.99	6 (6.7)	0 (0)	2 (4.8)	0.27
- Catheter-related DVT	8 (4.7)	3 (2.5)	5 (9.8)	0.055	4 (12.5)	1 (5.3)	0.64	4 (4.4)	1 (2.7)	3 (7.1)	0.64
Total patients with venous events	43 (25.4)	22 (18.6)	21 (48.8)	0.004	13 (40.6)	8 (42.1)	0.99	18 (20)	8 (21.6)	17 (40.5)	0.035
Arterial and venous events [N (%)]											
- Myocardial infarction + DVT/PVT	1 (0.6)	0 (0)	1 (2)	0.3	1 (3.1)	0 (0)	0.99	0 (0)	1 (2.7)	0 (0)	0.17
- Stroke + DVT/PVT	0 (0)	0 (0)	0 (0)	-	0 (0)	0 (0)	-	0 (0)	0 (0)	0 (0)	-
- Limb ischemia + DVT/PVT	3 (1.8)	2 (1.7)	1 (2)	0.99	0 (0)	1 (5.3)	0.37	2 (2.2)	0 (0)	1 (2.4)	0.65
Total patients with arterial and venous events	4 (2.4)	2 (1.7)	2 (3.9)	0.58	1 (3.1)	1 (5.3)	0.99	2 (2.2)	1 (2.7)	1 (2.4)	0.99

DVT: Deep vein thrombosis; PVT: Pulmonary vein thrombosis





Figure 1





Figure 2